Avalo Therapeutics, Inc.
NASDAQ:AVTXBiotechnology
-$0.34 today
- Market cap
- $387.41M
- Beta
- 0.82
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$4.21
Volume 1.58M
Average 1.61M
AVTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Avalo Therapeutics, Inc.NASDAQ: AVTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $19.63M (cash outflow) rose 49.3% year over year, ahead of the -216.1% change in trailing-twelve-month net income. Sequentially, it rose 43.1% from the prior quarter. Over 3 fiscal years it compounded at +23.4% a year.
Context
- Net income amounted to 132642.4% of revenue in FY2025, up 124676.6 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 12 analysts of -$32.99M (-57.8%) for the fiscal year ending Dec 2026, a slowdown from the +122.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.63M+43.1% QoQ
- Last fiscal yearDec 2025
- -$78.26M+122.8% YoY
- LTMMar 2026
- -$84.74M-216.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +49.3% | +22.4% | -26.9 pp |
| 1 year | +122.8% | -57.8% | -180.6 pp |
| 3-year CAGR | +23.4% | -25.5% | -48.9 pp |
| 5-year CAGR | -21.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (78.26M) USD
- Year-over-year change
- -122.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (78.26M) | -122.8% |
| FY2024 | 2024-12-31 | (35.13M) | -11.4% |
| FY2023 | 2023-12-31 | (31.54M) | +24.3% |
| FY2022 | 2022-12-31 | (41.66M) | +50.6% |
| FY2021 | 2021-12-31 | (84.38M) | — |
Net Income vs competitors
How AVTX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -216.1% is the lowest of 9, against a peer median of +0.2%.
- Net income amounts to 143627.1% of revenue for AVTX, versus a peer median of 179.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $263.86M USD | +77.1% | +22.8% | 291.6% | |
| LTM Mar 2026 | $104.29M USD | +8.2% | -6.9% | — | |
| LTM Mar 2026 | $84.74M USD | -216.1% | +23.4% | 143627.1% | |
| LTM Mar 2026 | $78.15M USD | +141.3% | -19.7% | — | |
| LTM Jun 2026 | $71.19M USD | -60.8% | +18.5% | 67.8% | |
| LTM Mar 2026 | $69.66M USD | -46.5% | -9.3% | 832.6% | |
| LTM Mar 2026 | €41.2M EUR | -7.9% | +14.1% | 140477.1% | |
| LTM Mar 2026 | $33.24M USD | +155.6% | — | 61.9% | |
| LTM Mar 2026 | $26.79M USD | -81.0% | — | 11.5% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding AVTX) | — | +0.2% | +3.6% | 179.7% | |
Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (84.38M) | (41.66M) | (31.54M) | (35.13M) | (78.26M) |
| Depreciation & Amortization | 1.66M | 166K | 158K | 169K | 344K |
| Deferred Income Tax | 22K | 28K | 14K | 114K | 165K |
| Stock-Based Compensation | 8.17M | 7.55M | 3.48M | 5.85M | 13.62M |
| Change in Working Capital | 2.84M | (60K) | (9.24M) | (4.71M) | 3.84M |
| Accounts Receivables | 1.12M | 2.88M | 1.78M | (475K) | 0 |
| Inventory | (35K) | 18K | 20K | 0 | 0 |
| Accounts Payables | 796K | (487K) | (2.44M) | (163K) | (146K) |
| Other Working Capital | 961K | (2.47M) | (8.61M) | (4.07M) | 3.99M |
| Other Non-Cash Items | 794K | 7.22M | 6.46M | (15.35M) | 8.83M |
| Operating Cash Flow | (70.89M) | (26.75M) | (30.68M) | (49.06M) | (51.46M) |
| Capital Expenditures | (113K) | (95K) | (158K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 356K | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (113.72M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 31.31M |
| Other Investing Activities | 0 | 0 | 25K | 0 | 690K |
| Investing Cash Flow | (113K) | (95K) | (133K) | 356K | (81.72M) |
| Debt Repayment | 32.9M | (14.81M) | (21.24M) | 0 | 0 |
| Common Stock Issued | 71.93M | 107K | 46.22M | 115.63M | 15.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.93M | 0 | 67K | 60.22M | (510K) |
| Financing Cash Flow | 106.76M | (14.7M) | 25.04M | 175.85M | 14.59M |
| Effect of Forex Changes | 0 | 96K | 0 | 0 | 0 |
| Net Change in Cash | 35.76M | (41.45M) | (5.77M) | 127.15M | (118.59M) |
| Free Cash Flow | (71.01M) | (26.85M) | (30.84M) | (49.06M) | (51.46M) |
Avalo Therapeutics, Inc.
NASDAQ:AVTX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.